Retrospective analysis evaluates Ninjin'yoeito's impact on chemotherapy tolerance and side effects in stage III colorectal cancer, suggesting benefits in treatment management.
Objectives: Adjuvant chemotherapy (AC) is the standard treatment for stage III colorectal cancer (CRC). However, its effectiveness is limited owing to adverse effects, particularly chemotherapy-induced peripheral neuropathy (CIPN). The objective of this study was to evaluate the real-world efficacy of Ninjin'yoeito (NYT), a traditional Kampo medicine, in improving chemotherapy tolerance and reducing adverse effects during AC with capecitabine plus oxaliplatin (CAPOX).
No takes yet. Share an insight, caveat, or question.
Kasahara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: